Target intelligence / Profile preview

Artemin (ARTN)

Target
ARTN
Molecular classification
Growth factor, Secreted ligand, Neurotrophic factor, Member of glial cell line-derived neurotrophic factor (GDNF) family ligands, TGF-beta superfamily protein
01

Overview

Artemin (ARTN) is a secreted growth factor in the glial cell line-derived neurotrophic factor (GDNF) family and a member of the broader TGF-beta superfamily. The ARTN gene encodes a preproprotein that is proteolytically processed to form a disulfide-linked homodimer serving as the mature, active protein. Artemin binds preferentially to the GFRα3 coreceptor, which, in association with the RET receptor tyrosine kinase, transduces intracellular signals crucial for neuron survival, differentiation, migration, and axonal growth in both the peripheral and central nervous system. Artemin also acts via alternative receptors, such as NCAM, contributing to its effects on neuronal regeneration. Beyond neurotrophic functions, ARTN is implicated in tumor growth, metastasis, therapy resistance (notably in breast cancer), and certain developmental and inflammatory conditions. Its signaling pathways and tissue-specific actions make artemin a promising, but potentially risky, therapeutic target and disease biomarker.

Other names
EnovinNeublastinEVNNBNEnovin, neurotrophic factorARTarteminneublastin
02

Mechanism of action

Activation of GFRα3–RET receptor complex: Artemin binds GFRα3, forming a receptor complex with RET (a receptor tyrosine kinase), which triggers intracellular signaling pathways (e.g., MAPK, Akt, Src) regulating survival, growth, and differentiation of neurons. Alternative signaling via NCAM: Artemin also directly interacts with neural cell adhesion molecule (NCAM), modulating alternative signal transduction pathways, particularly in neurite outgrowth and neuroprotection, even in the absence of RET.

03

Biological functions

Neuronal survivalNeuronal differentiationNeurite outgrowthCell proliferationCell migrationSignal transductionCNS and PNS developmentTumor progression
04

Disease associations

Neurodegenerative diseasesNeuropathic painCancersSpinal cord injuryPotential roles in gastrointestinal disorders
05

Safety considerations

Tumorigenicity and cancer riskPotential effects on neuronal plasticity
06

Interacting drugs

No widely approved drugs specifically target artemin as of 2025; peptidomimetics such as artefin act as functional agonists/mimetics in preclinical models. There are indirect therapies targeting the ARTN-RET-GFRα3 signaling axis.
07

Biomarkers

RET and GFRα3 expressionARTN mRNA/protein levels

Beyond the preview

Go deeper on Artemin (ARTN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artemin (ARTN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call